Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperprolactinemia. Evaluation and management.

R E Blackwell1

  • 1Division of Reproductive Biology and Endocrinology, University of Alabama, Birmingham.

Endocrinology and Metabolism Clinics of North America
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A one-year experience with a capitated health care plan for infertility.

Fertility and sterility·2001
Same author

The holmium:yttrium-aluminum-garnet laser in wrist arthroscopy: a five-year experience in the treatment of central triangular fibrocartilage complex tears by partial excision.

The Journal of hand surgery·2001
Same author

Constructing a financial case for a computerized patient data management system (PDMS) in a cardiothoracic intensive care unit.

Medical informatics and the Internet in medicine·2000
Same author

Hidden costs of infertility treatment in employee health benefits plans.

American journal of obstetrics and gynecology·2000
Same author

Reproductive medicine and research: contract laboratories vs. the university-based researcher.

Fertility and sterility·2000
Same author

Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women.

Fertility and sterility·1997
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Hyperprolactinemic syndromes are common, lifelong disorders in men and women. Recent advances simplified management, but understanding pituitary tumors and developing targeted therapies remain challenges.

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Oncology

Background:

  • Hyperprolactinemic syndromes encompass diverse disorders affecting various age groups.
  • These conditions are prevalent in both sexes, necessitating lifelong management.
  • Significant advancements in understanding and managing these syndromes have occurred over the past two decades.

Purpose of the Study:

  • To review the current state of knowledge regarding hyperprolactinemic syndromes.
  • To highlight progress in management while identifying areas needing further research.
  • To discuss the challenges in understanding pituitary tumor dynamics and developing novel therapies.

Main Methods:

  • Comprehensive literature review of hyperprolactinemic syndromes.
  • Analysis of recent advancements in diagnosis and treatment.

Related Experiment Videos

  • Identification of knowledge gaps in pituitary tumor biology and therapeutic strategies.

    • Main Results:

    • Management of hyperprolactinemic syndromes has been significantly simplified.
    • Understanding of the origin, dynamics, and natural history of pituitary tumors remains limited.
    • Effective tumoricidal therapies or central neurotransmitter-modulating medications are not yet available.

    Conclusions:

    • While management has improved, fundamental questions regarding pituitary tumors persist.
    • Further research is crucial for developing targeted therapies and addressing underlying neurotransmitter dysregulation.
    • Future reviews will likely focus on these unresolved aspects of hyperprolactinemia.